key: cord-0861163-yh532681
authors: Peluso, Michael J.; Hellmuth, Joanna; Chow, Felicia C.
title: Central Nervous System Effects of COVID-19 in People with HIV Infection
date: 2021-11-29
journal: Curr HIV/AIDS Rep
DOI: 10.1007/s11904-021-00582-x
sha: 54c8d9d3d4de41cc88d7e9bfff5f18eec97f260c
doc_id: 861163
cord_uid: yh532681

The convergence of the HIV and SARS-CoV-2 pandemics is an emerging field of interest. In this review, we outline the central nervous system (CNS) effects of COVID-19 in the general population and how these effects may manifest in people with HIV (PWH). We discuss the hypothetical mechanisms through which SARS-CoV-2 could impact the CNS during both the acute and recovery phases of infection and the potential selective vulnerability of PWH to these effects as a result of epidemiologic, clinical, and biologic factors. Finally, we define key research questions and considerations for the investigation of CNS sequelae of COVID-19 in PWH.

status and cerebrovascular disease constituted the majority of syndromes reported [24] . Neurologic involvement during acute SARS-CoV-2 infection may be more common in older individuals or in those with severe illness [25, 26•] . In one study of 58 critically ill patients in the intensive care unit (ICU) in France, agitation and/or confusion were present in 69% when sedation was lifted [27] . One-third of patients had evidence of ongoing altered mental status at the time of discharge. The presence of neurologic manifestations in acute SARS-CoV-2 infection may also predict higher in-hospital mortality independent of age and disease severity [28] .

It may be challenging to differentiate encephalopathy due to the direct or indirect effects of SARS-CoV-2 infection from the impact of critical illness, prolonged ICU hospitalization, and other medical issues (e.g., metabolic derangements, medication toxicity) on the brain. While some degree of encephalopathy is prevalent in hospitalized patients with COVID-19, encephalitis, defined as inflammation of the brain parenchyma by neuroimaging or cerebrospinal fluid [CSF] analysis, occurs infrequently [29] [30] [31] . In brain autopsy studies, mild non-specific inflammation (e.g., perivascular, parenchymal, and leptomeningeal lymphocytic infiltrates), acute hypoxic-ischemic injury, and microvascular changes are commonly reported, whereas frank vasculitis or meningoencephalitis are not [32, 33•, 34] .

Mounting evidence points to elevated cerebrovascular risk during acute SARS-CoV-2 infection. In a study of 1916 patients who were hospitalized or sought emergency care at a single center in New York City over 2 months, 31 (1.6%) had an acute ischemic stroke compared with 3 of 1486 influenza patients (0.2%; derived from historical data) [35] . Similar to other neurologic complications of COVID-19, patients who develop cerebrovascular disease may be older and more likely to suffer from cardiometabolic comorbidities (e.g., hypertension, diabetes mellitus) and from more severe SARS CoV-2 infection [36] . In contrast, other studies have raised the specter of an association between asymptomatic or mild SARS-CoV-2 infection and elevated stroke risk in the young [37, 38] .

Following acute illness, an unknown but likely substantial number of people experience post-acute sequelae of SARS-CoV-2 infection (PASC) [17] . Initially identified in convenience samples [18, 19•, 39-41] , efforts have been made to estimate the prevalence of PASC in more representative samples, although these have typically involved short followup [42, 43] or have been limited to hospitalized patients [44, 45••] . Recently, preliminary data on the frequency of PASC have emerged in larger and more representative cohorts [46, 47] , although true population-level studies are urgently needed. Post-acute neurologic sequelae include cognitive changes, sleep disorders, headache, neuropathy, tinnitus, vertigo, dysgeusia, anosmia/phantosmia, and dysautonomia; mood symptoms are also common [18, [39] [40] [41] [46] [47] [48] .

Persistent cognitive changes are a predominant feature of CNS PASC. People can experience new difficulties staying focused (attention), holding onto and manipulating information (working memory), remembering recent events that improves with cues (executive function), and slowed thinking (processing speed). Collectively, these symptoms suggest fronto-executive brain network dysfunction. Cognitive difficulties now reported in several cohorts [39] [40] [41] , including in non-hospitalized individuals [18, 19 •] , can persist longer than 8 months [39] . Importantly, there appears to be a considerable impact on quality of life [19•, 39] , which corroborates patient-driven descriptions of PASC [49] . A clear underlying mechanism or therapeutic approach has yet to be identified.

While there was initial concern that PWH would exhibit increased vulnerability to SARS-CoV-2 infection based on greater susceptibility to other respiratory pathogens [2, 50] , studies to date have found comparable or lower incidence of COVID-19 among PWH [3, [51] [52] [53] [54] . Although early studies suggested that PWH were at similar risk for severe COVID-19 as those without HIV infection [55] [56] [57] [58] , further efforts have indicated that those with a higher burden of medical comorbidities and/or incomplete immune reconstitution are likely to be at increased risk for more severe outcomes [59, 60] . No data are currently available on the clinical manifestations of the post-acute phase of SARS-CoV-2 infection and COVID-19 recovery in PWH, although studies are underway [61] .

Overlap or synergy in potential mechanisms driving neurologic complications of COVID-19 and HIV may place PWH with COVID-19 at higher risk for CNS dysfunction and/or injury (Fig. 1) . Of particular interest is how cognitive changes associated with COVID-19 may be similar to and interface with the virally mediated cognitive disorder of HIV, known as HIV-associated neurocognitive disorder (HAND). The clinical presentation of HAND, which may impact up to one-third of PWH on ART [62] , is strikingly similar to the executive dysfunction seen following COVID-19 [63] . However, one notable difference between patients with COVID-19 and HIV-associated cognitive impairment is the temporal onset of symptoms. Based on our current knowledge, cognitive changes appear acutely or within the first few months following COVID-19, while HAND can develop after years of sustained viral suppression on antiretroviral therapy. This may hint at a critical distinction between the impact of these two viruses on the CNS. HIV causes a chronic infection and persists in latently infected cells in reservoirs established early in infection, including in the CNS. The presence of persistent HIV-infected cells in CSF has been linked to worse cognition in PWH [64] . In contrast, while we are still early in our understanding of the trajectory of SARS-CoV-2 infection and the potential for viral persistence [65] , including in immunocompromised patients [66, 67] and patients with severe disease [68] , most patients appear to be able to effectively clear SARS-CoV-2 infection. However, if SARS-CoV-2 can persist in the CNS long term, as has been shown for other human coronaviruses [69, 70] , the prospect of ongoing neurologic injury and delayed neurologic dysfunction may be greater. Furthermore, mechanisms underlying encephalopathy in the setting of acute SARS-CoV-2 infection may diminish existing cognitive reserves and unmask or magnify cognitive impairment in PWH. In our own clinical practice, some patients with HAND have reported worsening of cognitive symptoms following COVID-19.

Preliminary data and expert opinion suggest that one or more of several mechanisms might contribute to the potential neurologic effects of COVID-19 in PWH:

1. Altered immune response, inflammation, and immune activation: Systemic and CNS inflammation and immune activation, which can remain elevated in PWH even after viral suppression with ART [71] [72] [73] [74] , have been implicated in the pathogenesis of complications associated with long-term HIV infection, including HAND [75] [76] [77] . Activation of inflammatory pathways in acute SARS-CoV-2 infection could compound the impact of chronic inflammation on the CNS in PWH [78] [79] [80] . One study demonstrated marked intrathecal inflammation, measured by CSF neopterin and b 2 -microglobulin, in hospitalized patients with COVID-19 and neurologic symptoms, although CSF pleocytosis, elevated IgG index, and evidence of blood-brain barrier disruption were absent [81] . Furthermore, immune activation and inflammation, either systemically or in the tissues, may persist after acute COVID-19 [17, 39] . Levels of soluble markers of inflammation (e.g., interleukin-10 (IL-10), macrophage-inflammatory protein-1, interferon-inducible protein -10 (IP-10)) have been shown to be elevated in SARS-CoV-2 convalescent plasma donors compared with healthy blood donors without COVID-19 [82•] . If this is the case, ongoing immune dysregulation may contribute to post-COVID cognitive changes, to which PWH might be particularly susceptible.

and human brain organoid studies have demonstrated direct SARS-CoV-2 invasion into the CNS with resulting neuronal death [33 •, 83•, 84] . In one postmortem study, SARS-CoV-2 infection was identified in areas of cerebral microinfarcts, raising the possibility that direct viral invasion may contribute to CNS injury and neurologic symptoms in COVID-19 [83•] . However, despite evidence of neuroinvasive potential of SARS-CoV-2, we do not yet know the frequency of this and the precise relationship between neuroinvasion and the development of acute and post-acute neurologic sequelae. Whereas identification of SARS-CoV-2 RNA from CSF has been rare [30, 81, 84, 85•] , HIV RNA is readily measured in the CSF within days to weeks of infection [15, 86] and in persons with untreated chronic infection [87] . The degree of CNS injury related to direct viral Fig. 1 Summary of the potential overlap between known or suspected mechanisms underlying central nervous system manifestations of SARS-CoV-2 and HIV infection invasion, immune activation, and neuroinflammation may be dictated by events during acute HIV infection, similar to the establishment of an immune set point early in HIV infection, which predicts later decline and disease progression. Very early ART initiation may mitigate HIV-associated CNS injury [88, 89] , although this is often not logistically feasible, and risk for HAND persists even with sustained viral suppression [90] .

The presence and severity of HAND is associated with markers of brain injury, including neurofilament light chain (NFL), a protein present in myelinated axons of neurons [91, 92] . Similarly, in a study of hospitalized patients with moderate to severe COVID-19, NFL and/ or glial fibrillary acidic protein (GFAP), an astroglial injury/activation marker, were elevated [93•] . This finding implies that CNS injury, rather than dysfunction of intact brain cells, occurs in some patients with moderate-to-severe COVID-19. The clinical consequences of this injury, which may be related to direct viral invasion or other mechanisms (e.g., persistent immune activation), could be especially relevant to PWH with ongoing HIV-related neurologic injury. 3. Post-infectious autoimmunity: Given the infrequent detection of SARS-CoV-2 neuroinvasion, some data suggest that CNS injury or dysfunction is caused by immune-mediated mechanisms that occur secondary to systemic infection. A recent study found that 5 of 7 hospitalized COVID-19 patients with a spectrum of neurologic issues displayed evidence of CNS autoantibodies [23] . Further work is needed to ascertain whether autoimmunity plays a role in PASC. Autoimmune phenomena are sometimes associated with the immune dysregulation that characterizes HIV infection [93 •, 94-96] , and it is unknown whether the autoimmune risk in SARS-CoV-2 is modified by HIV infection. 4. Neurovascular injury: The long-term projections for brain health and recovery after SARS-CoV-2 infection may be influenced by mechanisms driving neurovascular risk during acute infection, including a dysfunctional immunologic and endothelial response triggering cerebral microvascular injury and thrombosis [34] . Furthermore, subclinical microvascular injury triggered by acute infection may not become clinically apparent until later in the course of recovery. As has been shown with other systemic infections [97, 98] , cerebrovascular risk associated with COVID-19 may also remain elevated beyond the acute period. The proposed mechanisms by which SARS-CoV-2 may lead to elevated cerebrovascular risk may be particularly relevant for PWH. PWH contend with a heightened risk of cerebrovascular injury, attributed in part to chronic systemic immune activation and inflammation [7, 9] . Cerebrovascular disease and associated cardio-vascular comorbidities, in turn, are major contributors to HIV-associated cognitive impairment. In fact, cardiovascular risk factors may play a greater role in the development of cognitive impairment than HIV disease activity [99, 100] , especially among individuals with treated infection. Thus, for PWH, the immunologic and inflammatory response to COVID-19 may serve as an unwelcome "second hit," further compounding cerebrovascular risk and cognitive injury in this at-risk population. Studies have supported the concept of a cumulative infectious burden contributing to cerebrovascular risk, in which individual infections may not surpass thresholds to impact stroke risk but several infections in aggregate can [101] . 5. Syndemic comorbidities: Syndemic comorbidities in PWH, including substance use and metabolic disorders, may increase risk for contracting SARS-CoV-2 infection and lead to more severe disease and worse clinical outcomes [1••, 102] . These comorbidities may also contribute to the development of CNS injury in PWH with SARS-CoV-2 infection. Use of some substances has been linked to structural brain injury and long-term impairments in cognitive function in PWH [103, 104] , even after initiation of ART [105] . PWH who use stimulants can experience challenges navigating the HIV care continuum, resulting in barriers to achieving and maintaining virologic suppression [106] , which is critical to mitigating the inflammatory response in HIV. Furthermore, plasma and CSF inflammation and immune activation are heightened among PWH with a history of current and prior substance use [105, 107] . Amplification of immune dysregulation is one plausible mechanism by which substance use could increase susceptibility to CNS injury in PWH. Similarly, altered immune responses and chronic inflammation observed in metabolic disorders, including obesity and type 2 diabetes mellitus [108] [109] [110] , are proposed contributing factors to increased risk of SARS-CoV-2 infection and of severe disease. As with substance use, these pathways, which may mediate the association between metabolic disorders and HAND [111] , could also intensify CNS injury associated with COVID-19 in PWH.

Understanding the epidemiology and pathogenesis of neurologic complications of SARS CoV-2 infection will inform our approach to investigating potential CNS effects of COVID-19 in PWH. The optimal study approach will depend on the specific research questions that are of greatest interest to PWH and their providers. Although there are many potential questions related to CNS effects of COVID-19 in PWH (Table 1) , we believe four are key: within the population of PWH in a certain geographic region will require cohorts representative of the full spectrum of individuals with HIV infection who acquire SARS-CoV-2. Equally important to the epidemiologic questions is the utilization of meaningful comparator groups. An ideal study design would include clinical and biologic data from prior to and following the SARS-CoV-2 pandemic. Large observational cohorts of HIV infection [112, 113] that include a subset of individuals who developed COVID-19 could be leveraged to conduct such studies. Studies that are unable to evaluate pre-COVID-19 timepoints in PWH will require thoughtfully selected comparator groups. Depending on the question for investigation, this might be people with COVID-19 without HIV infection, PWH without COVID-19, or people with neither a history of HIV nor SARS-CoV-2 infection. Substantial effort will be required to ensure that these comparator groups are constructed in a way that minimizes the risk of selection biases that could arise from differential forces driving recruitment and inclusion. In some settings, oversampling of certain groups may be needed to facilitate inclusion of comparator groups that are sociodemographically similar to those with HIV infection, especially in light of the changing HIV epidemic. In the USA, this might include purposeful oversampling of specific demographic groups (e.g., Black and Latinx individuals, women) or groups with certain risk factors (e.g., men who have sex with men, injection drug users). In addition, as the neurologic burden of HIV infection has been increasingly recognized in resource-limited settings, global populations must be included in these research efforts. 

While electronic medical record (EMR)-derived data can be used to measure neurologic effects of COVID-19 among those hospitalized during the acute period, variability in access to care, provider assessments, symptom screening, and participant reporting will complicate the use of these data for non-hospitalized individuals and for all individuals during the post-acute period. In addition, the quality of measurements is relevant. Most existing studies have queried participant symptoms through self-report or interview. Few have included objective testing, which will require a combination of structured assessments, neurologic examination, and neuropsychological testing. In our experience, routine cognitive screening tests developed for the detection of dementia, such as the Montreal Cognitive Assessment and Mini-Mental State Examination, may not utilize sensitive enough thresholds to detect the cognitive inefficiencies observed following COVID-19, particularly as this population includes a younger age range of patients [17] . Collection of data on the abovementioned syndemic comorbidities, among other conditions that may co-occur with HIV infection (e.g., cardiovascular disease, psychiatric illness) and can affect brain health, will be pertinent to evaluating the independent contributions of COVID-19 to CNS injury and whether HIV modifies this relationship.

In line with the importance of studying populationbased cohorts that reflect the distribution of demographic and socioeconomic factors in communities affected by COVID-19, these considerations are also germane to the investigation of potential CNS effects of COVID-19. Some of these factors have been associated not only with risk of SARS-CoV-2 infection but also with differential outcomes during both the acute and recovery phases of COVID-19 [47, [114] [115] [116] and with the development or severity of HAND [117] [118] [119] . Selection of neuropsychological tests that can measure cognitive function across diverse populations will be critical in the assessment of cognitive effects of SARS-CoV-2 infection [120] . Furthermore, data on social determinants of brain health (e.g., nativity and acculturation; language; education; literacy; psychosocial stress; occupation; economic and financial status; residential characteristics) will be essential to accurately interpret neuropsychological test results [120] . Considerations of these factors and how they impact brain health have been pioneered for decades in HIV research [117, [121] [122] [123] . Drawing from lessons learned in international multi-site studies [124, 125] on the evaluation of cognitive function in PWH across countries, languages, and educational backgrounds will also inform the approach to cognitive testing in patients with COVID-19.

To understand the mechanisms driving neurologic involvement of SARS CoV-2 infection and interactions in PWH, we will need longitudinal data on systemic and CNS inflammation, neuronal injury, the presence of autoantibodies, and other biologic factors beyond the acute infection period. In addition to blood measurements, CSF analyses may be critical. For example, some patients with COVID-19 and neurologic complications have displayed differential inflammatory profiles in CSF compared with plasma, suggesting compartmentalized CNS immunologic responses may contribute to neurologic disease [23] . Available neuroimaging data in COVID-19 are almost exclusively in patients with acute SARS-CoV-2 infection [126, 127] . Information on neuroimaging findings in post-acute infection is limited. One study demonstrated volumetric and microstructural differences on brain MRI in patients with COVID-19 at 3 months after infection compared with age-and sex-matched controls without COVID-19 [128] . Neuroimaging techniques that assess longitudinal brain structure, function, and cerebrovascular physiology in the post-acute period may yield insights into the pathogenesis of CNS injury in COVID-19, as they have in the field of HIV [129] [130] [131] [132] [133] .

Through intense community advocacy, PWH were included in initial SARS-CoV-2 vaccine trials [134] [135] [136] , although the numbers were often small [137] . In order to understand the potential impact of SARS-CoV-2 preventative or therapeutic interventions on CNS sequelae of COVID-19 in PWH, PWH will need to be eligible for and engaged in clinical trials. Subgroup analyses should examine the effects of these interventions on PWH, who may exhibit distinct responses based on different underlying risks and comorbidities. Furthermore, studies of interventions for both symptom management and treatment that may be specific to PWH will need to be considered, designed, and implemented.

The convergence of the dual HIV and SARS-CoV-2 pandemics has highlighted the urgent need for research on potential interactions between these two infections. Much of our knowledge of how viruses impact the brain and brain function derives directly from HIV research. Leveraging research infrastructure and scientific methods developed over decades of effort in the fight against HIV has allowed for rapid, hypothesis-driven study of the CNS effects of COVID-19. Studies investigating the determinants of CNS effects of SARS-CoV-2 infection in PWH and whether HIV infection potentiates the mechanisms underlying these effects will further illuminate our understanding of virally-mediated CNS disease and could potentially improve the quality of life of millions of PWH worldwide.

Funding The authors acknowledge support related to this work from the following sources: NIH/NIAID T32 AI60530-12, NIH/ NIAID 3R01AI141003-03S1, NIH/NIAID R01AI158013, NIH R21TW010148, NIH/NIMH K23MH114724, NIH P30 AI027763, and the UCSF Resource Allocation Program.

The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.

HIV/AIDS in the era of COVID-19: a juxtaposition of two pandemics

The first 6 months of HIV-SARS-CoV-2 coinfection: outcomes for 6947 individuals

The interplay between HIV and COVID-19: summary of the data and responses to date

UNAIDS. Global HIV & AIDS statistics -2020 fact sheet

Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection

HIVinfected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality

Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment

Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection

Factors associated with worse cerebrovascular function in aging women with and at risk for HIV

Longitudinal management and outcomes of acute coronary syndrome in persons living with HIV infection. Eur Heart J Qual Care Clin Outcomes

Association of viral persistence and atherosclerosis in adults with treated HIV infection

Baseline 10-year cardiovascular risk scores predict cognitive function in older persons, and particularly women, living with human immunodeficiency virus infection

Silverberg MJ. HIV infection and incidence of ischemic stroke

Longitudinal brain atrophy patterns and neuropsychological performance in older adults with HIV-associated neurocognitive disorder compared with early Alzheimer's disease

Central nervous system viral invasion and inflammation during acute HIV infection

Cognitive disorders in people living with HIV

Post-acute COVID-19 syndrome

Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients

Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers

Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review

Stroke code presentations, interventions, and outcomes before and during the COVID-19 pandemic

Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19)

Immunologically distinct responses occur in the CNS of COVID-19 patients

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

Neurologic manifestations of hospitalized patients with coronavirus disease

A prospective study of neurologic disorders in hospitalized patients with COVID-19 in New York City

Neurologic features in severe SARS-CoV-2 infection

Neurologic syndromes predict higher in-hospital mortality in COVID-19

Neurological associations of COVID-19

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Du Pasquier R. Two patients with acute meningoencephalitis concomitant with SARS-CoV-2 infection

What can we learn from brain autopsies in COVID-19?

Neuropathological features of Covid-19

Microvascular injury in the brains of patients with Covid-19

Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza

Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study

Large-vessel stroke as a presenting feature of Covid-19 in the young

Treatment of acute ischemic stroke due to large vessel occlusion with COVID-19: experience from Paris

Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19. medRxiv

Patients with uncomplicated COVID-19 have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic

Sequelae in adults at 6 months after COVID-19 infection

Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network -United States

Follow-up of adults with noncritical COVID-19 two months after symptom onset

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Post-Acute Care Study Group: Persistent symptoms in patients after acute COVID-19

Attributes and predictors of long COVID

Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK -Office for National Statistics

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Potential impact of COVID-19 in people living with HIV: experience from previous 21st century coronaviruses epidemics

COVID-19 attack rate in HIV-infected patients and in PrEP users

Epidemiological, virological and serological features of COVID-19 cases in people living with HIV in Wuhan City: a population-based cohort study

Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study

The Spanish HIV/COVID-19 Collaboration: Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy : a cohort study

Clinical outcomes and immunologic characteristics of coronavirus disease 2019 in people with human immunodeficiency virus

COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients

COVID-19 ID Team: Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort

Clinical characteristics and outcomes in people living with human immunodeficiency virus hospitalized for coronavirus disease 2019

Characteristics, comorbidities, and outcomes in a multicenter registry of patients with HIV and coronavirus disease-19

Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa

New amfAR grants target intersection of HIV and COVID-19

HIV-associated neurocognitive impairment in the modern ART era: are we close to discovering reliable biomarkers in the setting of virological suppression?

The neuropsychological profile of symptomatic AIDS and ADC patients in the pre-HAART era: a meta-analysis

Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance

Evolution of antibody immunity to SARS-CoV-2

Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy

Persistence and evolution of SARS-CoV-2 in an immunocompromised host

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province

Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E

Pathogenesis of murine coronavirus in the central nervous system

Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy

Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection

The effect of initiation of antiretroviral therapy on monocyte, endothelial and platelet function in HIV-1 infection

Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14

Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection

Monocyte activation is associated with worse cognitive performance in HIV-infected women with virologic suppression

Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection

A dynamic COVID-19 immune signature includes associations with poor prognosis

Longitudinal analyses reveal immunological misfiring in severe COVID-19

An inflammatory cytokine signature predicts COVID-19 severity and survival

CSF biomarkers in patients with COVID-19 and neurologic symptoms: a case series

Cytokine and chemokine levels in coronavirus disease 2019 convalescent plasma. Open Forum Infect Dis. 2021;8:ofaa574. Provides mechanistic rationale for persistentinflammation as a potential driver of post-acute sequelae of SARS-CoV-2 infection

2021;218. Provides mechanistic rationale for viral invasion (and potential antigen persistence) as a driver of CNS manifestations of SARS-CoV-2 infection

Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Review identifying limited evidence of SARS-CoV-2 recovered from the cerebrospinal fluid

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden

Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment

Cognitive trajectories after treatment in acute HIV infection

Very early initiation of antiretroviral therapy during acute HIV infection is associated with normalized levels of immune activation markers in cerebrospinal fluid but not in plasma

Cognitive dysfunction in HIV patients despite long-standing suppression of viremia

The relationship of CSF and plasma cytokine levels in HIV infected patients with neurocognitive impairment

Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection

Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19

Outcomes of immunomodulatory and biologic therapy in people living with HIV

Autoimmune diseases and HIV infection: a cross-sectional study

Risk of acute stroke after hospitalization for sepsis: a case-crossover study

Hospitalization for infection and risk of acute ischemic stroke: the Cardiovascular Health Study

Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men

Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons

Infectious burden and risk of stroke: the northern Manhattan study

Double jeopardy: methamphetamine use and HIV as risk factors for COVID-19

An update of the review of neuropsychological consequences of HIV and substance abuse: a literature review and implications for treatment and future research

Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection

Past substance use affects central nervous system (CNS) inflammation in human immunodeficiency virus infection

Stimulant use and viral suppression in the era of universal antiretroviral therapy

Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection

Obesity and type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortality

Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships

COVID-19 in people with diabetes: understanding the reasons for worse outcomes

Abdominal obesity contributes to neurocognitive impairment in HIVinfected patients with increased inflammation and immune activation

COVID-19 symptoms and SARS-CoV-2 infection among people living with HIV in the US: the MACS/WIHS combined cohort study

Characteristics of the MACS-WIHS Combined Cohort Study: opportunities for research on aging with HIV in the longest US observational study of HIV

Racial disparities in COVID-19 mortality across Michigan, United States

Disparities in outcomes among COVID-19 patients in a large health care system in California: study estimates the COVID-19 infection fatality rate at the US county level

COVID-19 pandemic: disparate health impact on the Hispanic/Latinx population in the United States

HIV-associated neurocognitive disorders: the relationship of HIV infection with physical and social comorbidities

Multicenter European prevalence study of neurocognitive impairment and associated factors in HIV positive patients

Socioeconomic status and neuropsychological functioning: associations in an ethnically diverse HIV+ cohort

Perils of race-based norms in cognitive testing: the case of former NFL players

Neurocognitive impairment in Spanish-speaking Latinos living with HIV in the US: application of the neuropsychological norms for the US-Mexico border region in Spanish (NP-NUMBRS)

Neurobehavioral effects of HIV-1 infection in China and the United States: a pilot study

Differences in cognitive function between women and men with HIV

International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271

Human immunodeficiency virus-associated neurocognitive impairment in diverse resource-limited settings

The spectrum of neuroimaging findings on CT and MRI in adults with coronavirus disease (COVID-19)

Neuroimaging findings in COVID-19: a narrative review

Cerebral micro-structural changes in COVID-19 patients -an MRI-based 3-month follow-up study

Absence of cerebrospinal fluid signs of neuronal injury before and after immediate antiretroviral therapy in acute HIV infection

Association of brain structure changes and cognitive function with combination antiretroviral therapy in HIV-positive individuals

The regional pattern of abnormal cerebrovascular reactivity in HIV-infected, virally suppressed women

Functional connectivity in virally suppressed patients with HIV-associated neurocognitive disorder: a resting-state analysis

White matter structure alterations in HIV-1-infected men with sustained suppression of viraemia on treatment

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine

Novavax offers first evidence that COVID vaccines protect people against variants